TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. p.Phe508del homozygous subjects aged 6 years and older with cystic fibrosis~2. FEV1 ≥ 40% of predicted normal for age, gender and height (Knudson standards) or FEV1 \> 35% of predicted normal for age, gender and height at baseline, stable lung function during the preceding three months and no acute upper or lower respiratory infection or pulmonary exacerbation during the preceding four weeks~3. Hematology, serum chemistry, coagulation results at baseline with no clinically significant abnormalities that would interfere with the oral treatment with Orkambi® and with the study assessments, as judged by the investigator~4. Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator~5. Willing to remain on a stable medication regimen and administration of Orkambi® according to the FDA-approved patient labeling and the prescribing information for the duration of study participation -~Exclusion Criteria:~1. History of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering Orkambi®~2. An acute upper or lower respiratory infection or pulmonary exacerbation at baseline~3. Advanced liver disease as documented by sonography~4. Abnormal liver function at baseline, defined as ≥ 3 upper limit of normal in minimum 3 of the following: serum aspartate transaminase, serum alanine transaminase, gamma-glutamyl transpeptidase, or total bilirubin~5. Abnormal blood creatine phosphokinase at baseline~6. Abnormal renal function at baseline, defined as creatinine clearance \< 60 mL/min~7. Co-medication with strong Cytochrome P450, Family 3, subfamily A (CYP3A) inhibitors and inducers~8. Non-congenital lens opacities~9. Haemorrhoids (bleeding risk when taking rectal suction biopsies for ICM)~10. History of nasal surgery that removed the respiratory epithelium~11. Topical treatment of nostrils in the 3 days prior to baseline~12. Disturbing nasal aspects of secretions, erythema, crustae, ulcera, edema at baseline~13. Participation in a clinical study involving administration of a CFTR modulator~14. History of solid organ or haematological transplantation~15. History of alcohol, medication, or illicit drug abuse Exclusion criteria 1, 3, 4, 5, 6, 7 and 8 refer to known risk factors for the treatment with Orkambi®.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Therapy for RefrACTORy Migraine Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least one year history of Episodic or Chronic migraine headache symptoms~* At least 6 headache days per month~* Subject able to complete online daily headache log~Exclusion Criteria:~* Inability to understand the study or history of non-compliance with medical advice~* Currently taking a P2Y12 inhibitor~* Known hypersensitivity to Brilinta/ticagrelor~* History of stroke/transient ischemic attack (TIA) in the previous 6 months~* Active bleeding from any site~* Active peptic ulcer disease or upper gastrointestinal (GI) bleeding within six (6) months~* Migraine onset after 50 years of age~* Renal impairment: Creatinine Clearance \< 60 cc/min~* Severe hepatic impairment with total bilirubin \> 3.0 mg/dL~* Thrombocytopenia with platelet count \< 100,000 / ul~* History of intracranial hemorrhage~* Contraindications to blood thinner therapy or history of major bleeding episode while taking blood thinner therapy~* Need for chronic oral anti-coagulation therapy (i.e. Atrial Fibrillation)~* Need for chronic anti-platelet therapy (i.e. drug-eluting (DE) Stent), including daily aspirin use~* Need for daily nonsteroidal anti-inflammatory drug (NSAID) use~* Need for daily carbamazepine therapy or other strong CYP3A inhibitors or potent CYP3A inducers~* Need for simvastatin or lovastatin greater than 40 mg daily~* Symptomatic bradycardia or syncope~* Pregnancy or currently breast-feeding, or plan to become pregnant during the study period~* Planned surgery during the study time-frame~* Previously implanted patent foramen ovale (PFO), atrial septal defect (ASD), pacemaker, inferior vena cava filter, or left atrial appendage closure device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor 90 mg twice per day (Type: EXPERIMENTAL): Interventions include the following: All participants will have a loading dose of Ticagrelor (Brilinta) 180 mg administered in the office at the time of enrollment. Thereafter, for 28 days, Ticagrelor 90 mg tablet will be taken once in the morning and once in the evening, as close to 12 hours apart as possible. Each day, the subject will receive a text message reminder to login to the website, to record her/his headache activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Effect of Topical Tacrolimus 0.03% Versus Cyclosporine 0.05% in Dry Eyes of Secondary Sjogren Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as Secondary Sjogren syndrome according to the 2002 American European consensus group (AECG) criteria, which require the presence of well defined major connective tissue disease (such as rheumatoid arthritis and systemic lupus erythematosus.~* All patients show chronic symptoms of burning, foreign body sensation, itching in both eyes, abnormal Schirmer test \<5 mm wetting of the paper after 5 minutes, and abnormal tear breakup time (TBUT) \< 10 seconds.~* Wash out period of 30 days before start of the immunomodulatory eye drops included in the investigator's study~Exclusion Criteria:~1. Any inflammation or active structural changes in the iris or anterior chamber.~2. Patients receiving or who had received systemic cyclosporine or tacrolimus.~3. Patients receiving any systemic drug that can cause dry eye as some antidepressants , antihistaminic drugs , hormonal therapy...etc~4. Glaucoma.~5. Previous ocular surgery.~6. Use of any topical medication other than artificial tears.~7. Contact lens wearers.~8. Presence of any corneal infection.~9. Any corneal diseases (ulcer, opacity, scar, bullous keratopathy, symblepharon or tumors).~10. Deforming structural lid or conjunctival abnormality.~11. Pregnancy.~12. Prior diagnosis of any of the following conditions would exclude participation in AECG study :~Past head and neck radiation treatment Hepatitis C infection Acquired immunodeficiency disease (AIDS) Pre-existing lymphoma Sarcoidosis Graft versus host disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cyclosporins 0.05 % treated eyes (Type: ACTIVE_COMPARATOR): Topical Cyclosporins 0.05% eye drops twice in one eye for 3 months
- Tacrolimus 0.03% treated eyes (Type: ACTIVE_COMPARATOR): Topical Tacrolimus 0.03% eye drops twice in one eye for 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the knee~Exclusion Criteria:~* Other rheumatic disease, such as rheumatoid arthritis~* Active gastrointestinal ulcer during the last year~* Known allergy to analgesic drugs~* Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented disease progression during imatinib and sunitinib therapy OR intolerance to imatinib and/or sunitinib~* At least one measurable site of disease on CT/MRI scan~* PS≤2~* Normal organ, electrolyte, and bone marrow function~Exclusion Criteria:~* Previous treatment with nilotinib or any other drug in this class or other targeted therapy~* Treatment with any cytotoxic and/or investigational drug ≤ 4 weeks prior to study entry~* Impaired cardiac function~* Use of coumarin derivatives (i.e. warfarin)~* Women who are pregnant or lactating~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol Versus Dilapan-S for Cervical Preparation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medically eligible for dilation and evacuation at Planned Parenthood League of Massachusetts~* gestational age 12 weeks 0 days to 15 weeks 0 days as evaluated by ultrasound~* proficient in English or Spanish~* agreeing to study procedures, including randomization and surveys regarding demographics, medical and gynecological history, and assessments of pain and satisfaction~Exclusion Criteria:~* less than 18 years old~* cervical or uterine anomaly that the research physician deems may affect the difficulty of dilation or the abortion procedure~* inflammatory bowel disease~* contraindication to misoprostol use~* known intolerance or allergy to misoprostol or Dilapan-S~* inability to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 400mcg buccal misoprostol
- 2 (Type: EXPERIMENTAL): Dilapan-S, control: vitamin B-12 administered sublingually

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with moderate to severe stable Chronic Obstructive Lung Disease (COPD) Stage II or Stage III according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines.~* Patients with a post-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 30 % and/or \<80 % of the predicted normal, and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) \< 0.70 at screening.~* Current or ex-smokers who have a smoking history of at least 10 pack years~* Symptomatic patients according to daily diary data.~Exclusion Criteria:~* Pregnant or nursing (lactating) women.~* Women of child-bearing potential unless using adequate contraception.~* Patients with Type I or uncontrolled Type II diabetes.~* Patients with a history of long time interval between start of Q wave and end of T wave in the heart's electrical cycle (QT) syndrome or whose QT corrected for heart rate (QTc) measured at screening (Visit 2) (Fridericia's method) is prolonged~* Patients with paroxysmal (e.g. intermittent) atrial fibrillation~* Patients who have a clinically significant electrocardiogram (ECG) or laboratory abnormality at screening (Visit 2)~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NVA237 + indacaterol (Type: ACTIVE_COMPARATOR): None
- Placebo to NVA237 + indacaterol (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: YF476 and Type I Gastric Carcinoids

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients known to have gastric carcinoids associated with chronic atrophic gastritis and hypergastrinaemia, and who attend the outpatient clinic of the investigator;~* Men, postmenopausal women, premenopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophrectomy, or premenopausal women using reliable contraception: condom and spermicide or intrauterine device;~* Adults ≥ 18 years;~* Good general health; and~* Able to give fully-informed, written consent.~Exclusion Criteria:~* Women who are pregnant, lactating or using a steroid contraceptive;~* History of gastric surgery, apart from surgery for gastric carcinoids;~* Evidence of Zollinger-Ellison syndrome;~* Prolonged QTc interval (\>450 msec);~* Certain medicines and herbal remedies taken during the 7 days before visit 1;~* Previous treatment with somatostatin; or~* Participation in other clinical trials of unlicensed medicines within the previous 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- YF476 treatment (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Diurnal Rhythm in Natriuretic Peptide Levels

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 40 years~* Blood pressure less than 140/90~* Body Mass Index between 18.5 to 25 kg/m2 (lean) or 30 to 45 kg/m2 (obese)~* Self identified African-American or white individuals~* Willingness to comply with the study diet~* Provide informed consent~Exclusion Criteria:~* History of hypertension~* History of cardiovascular, renal, or liver disease~* Diabetes or use of glucose-lowering medications~* Use of vasoactive or diuretic medications~* Atrial fibrillation~* Anemia (Hematocrit \<41%)~* Abnormal serum sodium or potassium~* Abnormal liver function tests (\>3x upper limit of normal)~* Current smokers~* Regular users of non-steroid anti-inflammatory medications

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Study Individuals (Type: OTHER): Healthy self-identified African-American and white male participants will be screened. Study consent will be obtained, medical history and physical examination administered, and study eligibility determined based on the inclusion and exclusion criteria. Eligible subjects will meet a bio-nutritionist who will explain the 5 days of standardized diet at the screening visit and will review instructions for complying with the diet. If the subject agrees to adhere to the study diet, they will then be enrolled in the study (stratified by race).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of schizoaffective disorder~* A total Positive and Negative Symptoms of Schizophrenia (PANSS) score of \>= 60~* A score of \>= 16 on Young Mania Rating Scale (YMRS) or a score of \>= 16 on the Hamilton Depression Rating Scale (HAM-D 21)~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizoaffective disorder~* Patients with first episode psychosis~* Active substance dependence within previous 6 months~* Treatment with clozapine within 6 months of randomization~* A history of treatment resistance, defined by failure to respond to 2 adequate trials of antipsychotic medication~* Pregnancy, breast-feeding, or planning to become pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
- 003 (Type: EXPERIMENTAL): Paliperidone ER (3-12mg/day in 3 mg/day increments for 6 weeks)
- 002 (Type: PLACEBO_COMPARATOR): Placebo for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Overweight or obese subjects with BMI \> 30 kg/m2 with type 2 diabetes mellitus taking DPP4 inhibitors alone or in combination with metformin.~2. Women of childbearing potential will have a negative pregnancy test before initiation of medication and within 48 hours of receiving radioisotope.~Exclusion criteria:~1. Structural of metabolic diseases/conditions that affect the gastrointestinal system, or functional gastrointestinal disorders.~2. Irritable bowel syndrome~3. Bristol stool type classification 4-7 per Bowel Disease questionnaire.~4. Subjects with other treatment for type 2 diabetes mellitus.~5. Subjects with HbA1c \> 8%~6. Females who are pregnant or breastfeeding~7. Concomitant use of appetite suppressants, orlistat, phentermine-topiramate ER or lorcaserin.~8. Subjects who are not currently on treatment for cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological, endocrine (other than type 2 diabetes mellitus), and unstable psychiatric disease.~9. Subjects who have donated blood or plasma in the past 8 weeks.~10. Subjects who have participated in another study within the past 30 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Ox bile extract (Type: ACTIVE_COMPARATOR): Ox bile extract 500 mg tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo tablets taken orally twice daily for 28 (+/- 4) days Gastric Emptying test, Waist and hip measurements, Mixed oral glucose tolerance test, Blood tests

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who were diagnosed with AMI, including STEMI and NSTEMI, and underwent successful PCI and routine follow-up coronary angiography at the Second Affiliated Hospital of Zhejiang University School of Medicine between June 1, 2017 and May 31, 2020.~Exclusion Criteria:~* 1) prior treatment with any P2Y12 inhibitor;~* 2) need for long-term oral anticoagulation therapy;~* 3) previous coronary artery bypass grafting (CABG);~* 4) chronic renal dysfunction with estimated glomerular filtration rate (eGFR) \<30 mL/ (min·1.73 m2) or on hemodialysis;~* 5) liver cirrhosis ≥Child-Pugh B class;~* 6) cancer;~* 7) adjustment of dual antiplatelet therapy (DAPT) during follow-up;~* 8) inadequate coronary angiographic images.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Study Arms:
- ticagrelor maintenance treatment group (Type: None): Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and ticagrelor 90mg twice daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.
- clopidogrel maintenance treatment group (Type: None): Patients received dual antiplatelet therapy (DAPT) with aspirin 100mg daily and clopidogrel 75mg once daily for at least 9 months after PCI. Angio-IMR assessment was performed after primary PCI and during routine follow-up coronary angiography.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete